A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

Abstract Background Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) advanced breast cancer is a prevalent subtype among postmenopausal women. Despite the growing number of randomized clinical trials (RCTs) exploring this topic, the efficacy and safety of fi...

Full description

Bibliographic Details
Main Authors: Hanqiao Shao, Mingye Zhao, Ai-Jia Guan, Taihang Shao, Dachuang Zhou, Guo Yu, Wenxi Tang
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Medicine
Subjects:
HR-positive/HER2-negative
Advanced breast cancer
Efficacy
Safety
Network meta-analysis
Online Access:https://doi.org/10.1186/s12916-023-03238-2

Internet

https://doi.org/10.1186/s12916-023-03238-2

Similar Items